An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice

Summary

The factors responsible for the removal of injected factor IX (fIX) from the blood of individuals with haemophilia B are only partly understood, and may include binding to endothelial or subendothelial sites, passive extravasation related to size or charge, or interactions requiring fIX activation. To investigate these issues, we have produced and characterised recombinant fIX proteins with amino acid changes: Δ155–177, an internal deletion which removes most of the activation peptide while retaining the activation cleavage sites; S365A, which inactivates the serine protease activity of fIXa; and K5A, previously shown to eliminate fIX binding of endothelial/subendothelial collagen IV. All proteins were expressed in stably transfected HEK 293 cells, purified by immunoaffinity chromatography, and compared to the wild type HEK 293-derived protein (fIX (WT)). Mutant fIX proteins K5A and Δ155–177 exhibited 72 and 202% of the specific activity of fIX (WT), respectively; S365A was without activity. Following intravenous injection in haemophilia B (fIX knockout) mice, recoveries did not differ for fIX (WT) and Δ155–177, but were higher for K5A and S365A. The terminal catabolic halflife of Δ155–177, alone among the mutants, was increased, by 45% versus fIX (WT). Nine hours post-injection, the observed areas under the clearance curve (AUCs) of Δ155–177 and K5, but not S365A, were elevated 2-fold. Δ155–177 was equally effective as fIX (WT) in reducing blood loss following tail vein transection in haemophilia B mice. Our results suggest that deletion of the multiple sites of fIX post-translational modification found within the activation peptide eliminated important fIX clearance motifs.

Keywords

Factor IX - recombinant proteins - clearance - recovery - posttranslational Modifications

• References

• 1 Mannucci PM, Tuddenham EG. The hemophilias– from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
• 2 Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor VIIa/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of 3H- and 125I-labeled factor IX. Biochemistry 1983; 22: 4047-53.
• 3 van Dieijen G, Tans G, Rosing J. et al The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
• 4 Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem 1975; 250: 8883-8.
• 5 Neels J, van den Berg B, Mertens K. et al Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000; 96: 3459-s65.
• 6 Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Baillieres Clin Haematol 1996; 9: 259-71.
• 7 Lee C, Sabin C, Miners A. High cost, low volume care: the case of haemophilia. BMJ 1997; 315: 962-3.
• 8 Schramm W, Royal S, Kroner B. et al Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002; 8: 33-43.
• 9 Thompson AR. Factor IX concentrates for clinical use. Semin Thromb Hemost 1993; 19: 25-36.
• 10 Ewenstein BM, Joist JH, Shapiro AD. et al Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
• 11 Gui T, Lin HF, Jin DY. et al Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-8.
• 12 Cheung WF, Hamaguchi N, Smith KJ. et al The binding of human factor IX to endothelial cells is mediated by residues 3–11. J Biol Chem 1992; 267: 20529-31.
• 13 Schuettrumpf J, Herzog RW, Schlachterman A. et al Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2005; 105: 2316-23.
• 14 Vysotchin A, Medved LV, Ingham KC. Domain structure and domain-domain interactions in human coagulation factor IX. J Biol Chem 1993; 268: 8436-46.
• 15 Bond M, Jankowski M, Patel H. et al Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-7.
• 16 White II G, Beebe A, Nielsen B. Recombinant Factor IX. Thromb Haemost 1997; 78: 261-5.
• 17 Hortelano G, Xu N, Vandenberg A. et al Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules. Hum Gene Ther 1999; 10: 1281-8.
• 18 Jack GW, Beer DJ. Immunoaffinity chromatography. Methods Mol Biol 1996; 59: 187-96.
• 19 Sheffield WP, Mamdani A, Hortelano G. et al Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004; 126: 565-73.
• 20 Babson AL, Babson SR. Comparative evaluation of a partial thromboplastin reagent containing a nonsettling, particulate activator. Am J Clin Pathol 1974; 62: 856-60.
• 21 Wang L, Zoppe M, Hackeng TM. et al A factor IXdeficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A 1997; 94: 11563-6.
• 22 Hortelano G, Wang L, Xu N. et al Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia 2001; 7: 207-14.
• 23 Ni H, Blajchman MA, Ananthanarayanan VS. et al Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. Thromb Res 2000; 99: 407-15.
• 24 McCurdy TR, Gataiance S, Eltringham-Smith LJ. et al A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. J Lab Clin. Med 2004; 143: 115-24.
• 25 Yu Z, Tse FL. An evaluation of numerical integration algorithms for the estimation of the area under the curve (AUC) in pharmacokinetic studies. Biopharm Drug Dispos 1995; 16: 37-58.
• 26 Van Ryn-McKenna J, Ofosu FA, Hirsh J. et al Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-9.
• 27 Wolberg AS, Morris DP, Stafford DW. Factor IX activation by factor XIa proceeds without release of a free intermediate. Biochemistry 1997; 36: 4074-9.
• 28 Bond M, Jankowski M, Patel H. et al Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-17.
• 29 Lee EU, Roth J, Paulson JC. Alteration of terminal glycosylation sequences on N-linked oligosaccharides of Chinese hamster ovary cells by expression of betagalactoside alpha 2,6-sialyltransferase. J Biol Chem 1989; 264: 13848-55.
• 30 Wang WC, Cummings RD. The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 1988; 263: 4576-85.
• 31 Shibuya N, Goldstein IJ, Broekaert WF. et al The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2–6)Gal/GalNAc sequence. J Biol Chem 1987; 262: 1596-601.
• 32 Chang J-Y, Allen GA, Monroe DM. et al Role of the activation peptide in factor IX activation. Blood 2000; 96: 632a.
• 33 Keith Jr. JC, Ferranti TJ, Misra B. et al Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost 1995; 73: 101-5.
• 34 Fuchs HE, Trapp HG, Griffith MJ. et al Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest 1984; 73: 1696-703.
• 35 Marques JA, George JK, Smith IJ. et al A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro . Thromb Haemost 2001; 86: 902-8.
• 36 Syed S, Schuyler PD, Kulczycky M. et al Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997; 89: 3243-52.
• 37 White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
• 38 Gui T, Lin HF, Jin DY. et al Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo . Blood 2002; 100: 153-8.
• 39 Chang J, Jin J, Lollar P. et al Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273: 12089-94.